Author:
Wong Kit Man,King Gentry G.,Harris William P.
Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. CANCER TODAY provides data visualization tools that present current national estimates of the incidence, mortality, and prevalence of 36 cancer types in 185 countries, by sex and age group. https://gco.iarc.fr/today/online-analysis-multibars?v=2020&mode=cancer&mode_population=countries&population=900&populations=900&key=asr&sex=0&cancer=39&type=0&statistic=5&prevalence=0&population_group=0&ages_group%5B%5D=0&ages_group%5B%5D=17&nb_items=10&group_cancer=1&include_nmsc=0&include_nmsc_other=1&type_multiple=%257B%2522inc%2522%253Atrue%252C%2522mort%2522%253Afalse%252C%2522prev%2522%253Afalse%257D&orientation=horizontal&type_sort=0&type_nb_items=%257B%2522top%2522%253Atrue%252C%2522bottom%2522%253Afalse%257D. Accessed 20 Mar 2022.
2. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology. 2018;68(2):723–50. https://doi.org/10.1002/hep.29913.
3. Petrick JL, Kelly SP, Altekruse SF, McGlynn KA, Rosenberg PS. Future of Hepatocellular carcinoma incidence in the United States Forecast Through 2030. J Clin Oncol. 2016;34(15):1787–94. https://doi.org/10.1200/jco.2015.64.7412.
4. Crocenzi T, El-Khoueiry A, Yau T, et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study. J Clin Oncol. 2018;36(suppl):abstr 4013.
5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90. https://doi.org/10.1056/NEJMoa0708857.
Cited by
26 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献